Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof

A kind of compound, technology of spiro tricyclic, applied in the field of spiro tricyclic compounds and preparation thereof

Inactive Publication Date: 2012-06-27
SOUTHERN MEDICAL UNIVERSITY
View PDF17 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] As mentioned above, c-Met tyrosine kinase inhibitors have been reported in many literatures, and some monoclonal antibodies and synthetic small molecule compounds against c-Met or HGF are in phase 1-3 clinical trials. However, due to the well-known Uncertainty in clinical trials, no c-Met or HGF inhibitors have been approved as drugs yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof
  • Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof
  • Spirotricyclic compound, its preparation method, and pharmaceutical composition containing it as well as application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0289] 5-[1-(6-quinolinylmethyl)-1H-[1,2,3]triazol[4,5-b]pyrazin-6-yl]spiro[indoline-3,4' Synthesis of -piperidin]-2-one

[0290]

[0291] Step 1: Synthesis of {2-oxyspiro[indoline-3,4'-piperidinyl]-5-yl}boronic acid pinacol ester

[0292]

[0293] Under nitrogen, add 5-bromospiro[indoline-3,4'-piperidin]-2-one (140.6mg or 0.5mmol), bipinacol borate (140mg or 0.55mmol) and potassium acetate (147mg or 1.5mmol) in DMSO solution (0.2ml) was added PdCl 2 (dppf).CH 2 Cl 2 (20.4 mg or 0.025 mmol), nitrogen was bubbled into the resulting solution for 2 minutes, and then stirred at 80° C. for 16 hours. LC-MS showed that the reaction was complete. After cooling to room temperature, 2 mL of water was added and extracted with DCM (5 mL was used for 3 extractions). Combine the organic phases with Na 2 SO 4 After drying and concentration, 162 mg of the target product was obtained (yield: 98.7%). Mass Spectrum m / z: 328.07 [M+H + ], 329.08[M+H + , 100%], 330.11 [M+H + ].

...

Embodiment 2

[0297] 6-[1-(6-quinolinylmethyl)-1H-[1,2,3]triazol[4,5-b]pyrazin-6-yl]spiro[indoline-3,4' Synthesis of -piperidin]-2-one

[0298]

[0299] Step 1: Synthesis of {2-oxyspiro[indoline-3,4'-piperidinyl]-6-yl}boronic acid pinacol ester

[0300]

[0301] Referring to the method of Example 1, it was prepared from 6-bromospiro[indoline-3,4'-piperidin]-2-one, yield: 96.9%. Mass Spectrum m / z: 328.07 [M+H + ], 329.08[M+H + , 100%], 330.11 [M+H + ].

[0302] Step 2: 6-[1-(6-Quinolinylmethyl)-1H-[1,2,3]triazol[4,5-b]pyrazin-6-yl]spiro[indoline-3 , Synthesis of 4'-piperidin]-2-one

[0303] Prepare with reference to the method of Example 1. Yield: 73%. Mass Spectrum m / z: 463.23 [M+H + ].

Embodiment 3

[0305]1'-Methyl-5-[1-(6-quinolylmethyl)-1H-[1,2,3]triazol[4,5-b]pyrazin-6-yl]spiro[indole Synthesis of phen-3,4'-piperidin]-2-one

[0306]

[0307] Step 1: Synthesis of 5-bromo-1'-methylspiro[indoline-3,4'-piperidin]-2-one

[0308]

[0309] 5-Bromospiro[indoline-3,4'-piperidin]-2-one (1.686g or 6mmol) was suspended in 15mL THF, cooled to -78°C, and 1M NaN (SiMe 3 ) 2 THF solution (30mL or 30mmol). After the addition was complete, it was stirred at -78°C for 30 minutes, and then solid 2-chloro-N-(2-chloroethyl)-N-methylethylamine hydrochloride (1155 g or 6 mmol) was added. Stirring was continued for 30 minutes after the addition was complete, then raised to room temperature and stirred for two days. TLC showed that the reaction was complete, and 10 mL of 4M hydrochloric acid aqueous solution was carefully added to the pink suspension, then adjusted to pH ≈ 9 with concentrated ammonia water, and extracted with DCM (3 times with 80 mL for each extraction). Combine the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a spirotricyclic compound as shown in formula (I), and simultaneously discloses a preparation method of the compound and application thereof, as well as a pharmaceutical composition containing the spirotricyclic compound. Being an inhibitor of protein kinase, the compound in the invention can be used to treat diseases caused by abnormal protein kinase activity, such as tumors and the like.

Description

technical field [0001] The invention relates to the fields of organic chemistry and medicinal chemistry, in particular to a spirotricyclic compound, a preparation method thereof, a pharmaceutical composition containing the compound and an application thereof. Background technique [0002] Cancer and cardiovascular disease are two major diseases that seriously threaten human health and life. In particular, the incidence and mortality of cancer have been rising rapidly in recent years, surpassing cardiovascular disease to become the number one killer of human health. [0003] The proliferation, apoptosis, and metastasis of tumors are closely related to the abnormality of a certain link in a series of signal transduction pathways inside and outside cells. An important class of molecules in these signal transduction pathways are protein kinases. The abnormality of protein kinase activity is not only directly related to tumors, but also the main cause of a series of other human ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D519/00C07D471/10A61K31/4985A61K31/5025A61K31/519A61K31/52A61K31/4709A61P35/00A61P35/02A61P17/06A61P1/16A61P3/10A61P27/02A61P29/00A61P19/02A61P37/02A61P9/00A61P13/12
Inventor 张嘉杰金宏田元新朱正光李中皇王广发万山河叶连宝游文玮吴曙光
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap